Triple drug combo for EGFR-mutant lung cancer after osimertinib
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of three targeted drugs (osimertinib, cetuximab, and tucatinib) for people with EGFR-mutant lung cancer that has gotten worse after osimertinib. The goal is to see if this new combination can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or recurrent non-small cell lung cancer (NSCLC) that has spread to other parts of the body.
- Your cancer has a specific EGFR mutation (like Exon 19 deletion or L858R).
- You have already taken osimertinib (Tagrisso) and your cancer got worse while on it.
- You are able to have a tumor biopsy (or have a recent sample) after your cancer progressed on osimertinib.
- You have stable brain metastases (if any) and are not on steroids for them.
- Your overall health is good (ECOG 0 or 1), and your heart, kidney, and liver function are within safe limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for patients with advanced non-small cell lung cancer that has a specific EGFR mutation (Ex19del or L858R) and has started to grow again after at least six months on osimertinib. It combines two types of focused radiation with continued osimertinib to treat only the progressing spots while keeping the rest of the disease under control.
This Phase 3 trial tests whether starting osimertinib with or without bevacizumab helps people with advanced EGFR-mutant lung cancer live longer and control the cancer better. Your EGFR mutation test result and past treatments are key to whether you can join.
This Phase 2 trial tests combinations of targeted medicines to treat advanced non-small cell lung cancer (NSCLC) that has changes in both EGFR and MET genes. It is for people whose cancer continued to grow even after treatment with osimertinib, the most recent therapy.
This Phase 1 study tests whether combining MRX-2843 with osimertinib can help control advanced lung cancer that has specific EGFR gene changes. It is designed to find the safest dose and check early signs of tumor response.
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
This study tests adding chemotherapy (pemetrexed and carboplatin) to the targeted drug osimertinib (Tagrisso) for people with a specific type of advanced lung cancer (EGFR-mutated adenocarcinoma) that is not controlled well by osimertinib alone. The goal is to see if the combination helps people live longer or better.
Hear when a new Metastatic Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.